 Patients will be treated with bortezomib 1.3 mgm2, intravenously on days 1, 4, 8 and 11, and doxorubicin 20 mgm2, intravenously on days 1 and 8, every 21 days. Zinecard will be added at the 8th cycle and all subsequent cycles with doxorubicin. After the completion of 14 cycles, if there is no progression, bortezomib once a week at a dose of 1.6 mgm2 on days 1,8,15, every 28 days, will be administered alone. Treatment will continue unless disease progression or intolerable toxicity emerges see section 5 for detailed treatment plan and dose modifications. 